Respiratory Specimen Nucleic Acid Sars-Cov-2 Test
FDA product code QQX · Class II (moderate risk) · 21 CFR 866.3981 · Microbiology
A device to detect and identify nucleic acid targets in respiratory specimens from SARS-CoV-2 that cause COVID-19 is an in vitro diagnostic device intended for the detection and identification of SARS-CoV-2 nucleic acid targets in human clinical respiratory specimens from patients suspected of COVID-19 based on signs and symptoms of respiratory infections by their healthcare providers. The device is intended to aid in the diagnosis of COVID-19 in conjunction with other clinical, epidemiologic, and laboratory data or other risk factors.
11510(k) clearances
0PMA approvals
0recalls
Manufacturers
510(k) clearances
| 510(k) | Device | Applicant | Decision |
|---|---|---|---|
| K243396 | Aptima SARS-CoV-2 AssayQQX · Traditional | Hologic, Inc. | 02/13/2025SE |
| K240867 | cobas® SARS-CoV-2 Qualitative for use on the cobas® 5800/6800/8800 SystemsQQX · Traditional | Roche Molecular Systems, Inc. | 02/11/2025SE |
| K242109 | Xpert® Xpress CoV-2 plus (XPRS-COV2-10)QQX · Dual Track | Cepheid® | 01/15/2025SE |
| K241580 | Alinity m SARS-CoV-2 AMP Kit (09N78-096); Alinity m SARS-CoV-2 CTRL Kit (09N78-086)QQX · Traditional | Abbott Molecular | 12/06/2024SE |
| K233453 | Applied Biosystems TaqPath COVID-19 Diagnostic PCR KitQQX · Traditional | Life Technologies Corporation | 07/10/2024SE |
| K230440 | Xpert® Xpress CoV-2 plusQQX · Traditional | Cepheid® | 10/13/2023SE |
| K231306 | cobas SARS-CoV-2 Qualitative for use on the cobas 5800/6800/8800 SystemsQQX · Special | Roche Molecular Systems, Inc. | 06/01/2023SE |
| K213804 | cobas SARS-CoV-2 Qualitative for use on the cobas 6800/8800 SystemsQQX · Traditional | Roche Molecular Systems, Inc. | 10/22/2022SE |
| K212147 | Simplexa COVID-19 DirectQQX · Traditional | Diasorin Molecular, LLC | 09/13/2022SE |
| K221460 | BioFire COVID-19 Test 2QQX · Special | Biofire Defense, LLC | 07/25/2022SE |
| K211079 | BioFire COVID-19 Test 2QQX · Traditional | Biofire Defense, LLC | 11/01/2021SE |